<DOC>
	<DOCNO>NCT00658580</DOCNO>
	<brief_summary>The purpose study determine cisplatin-etoposide regimen improve survival comparison regimen contain etoposide without platinum derivative .</brief_summary>
	<brief_title>Randomized Study Cisplatin-Etoposide Versus Etoposide Regimen Without Cisplatin Extensive Small-Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Histological cytological diagnosis smallcell lung cancer Extensive disease ( i.e . disease distant metastasis include single irradiation field incorporate primary tumour , mediastinum supraclavicular lymph node ( ) ) Availability participate detailed followup protocol Presence evaluable measurable lesion Informed consent Prior treatment chemotherapy , radiotherapy surgery Performance status &lt; 60 Karnofsky scale A history prior malignant tumor , except nonmelanoma skin cancer situ carcinoma cervix cure cancer ( define diseasefree interval &gt; 5 year ) White blood cell &lt; 4000/mm3 Platelets &lt; 100000/mm3 Serum bilirubin &gt; 1.5 mg/100 ml Serum creatinine &gt; 1.3 mg/100 ml creatinine clearance &lt; 60 ml/min Recent myocardial infarction ( le 3 month prior date diagnosis ) Congestive cardiac failure cardiac arrhythmia uncontrolled medical treatment Uncontrolled infectious disease Serious medical psychological factor may prevent adherence treatment schedule</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Small cell lung carcinoma</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Phase III randomise study</keyword>
</DOC>